ReviewCurrent opinion in neurology2019
Neuromyelitis optica spectrum disorders: still evolving and broadening.
Review in Current opinion in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The spectrum of overlapping anti-NMDAR encephalitis and demyelinating syndromes: a systematic review of presentation, diagnosis, management, and outcomes.Annals of medicine · 2025Pooled it
- Oily fish and raw vegetable consumption can decrease the risk of AQP4-positive neuromyelitis optica spectrum disorders: a Mendelian-randomization study.Scientific reports · 2023Pooled it
- Neuromyelitis Optica Spectrum Disorders in Africa: A Systematic Review.Neurology(R) neuroimmunology & neuroinflammation · 2021Pooled it
- Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.Neurology(R) neuroimmunology & neuroinflammation · 2023Trial
- Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.Annals of neurology · 2021Trial
- Clinical characteristics and evolution of dural enhancement in NMOSD: A retrospective case series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- HLA Associations Differ by Ethnicity and Aquaporin-4 Antibody Status in Patients With Neuromyelitis Optica Spectrum Disorders.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.Journal of neurology · 2026Article
- Case Report: Overlap syndrome of anti-NMDA receptor encephalitis and MOG-associated disease in a pediatric patient-literature insights.Frontiers in immunology · 2026Review
- Lymphoplasmapheresis for Steroid-Refractory Neuromyelitis Optica Spectrum Disorder: A Real-World Multicenter Study in China.CNS neuroscience & therapeutics · 2025Article
- Incidence and Risk Factors for Serious Infections in Patients with Neuromyelitis Optica Spectrum Disorder: A Claims Database Study in Japan.Neurology and therapy · 2025Article
- Article
- Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD.Journal of neurology · 2025Article
- Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD.Journal of neurology · 2025Article
- Concomitant Sjögren's disease in patients with NMOSD: impacts on neurologic disease severity and recurrence.Arthritis research & therapy · 2025Article
- Usage status of biologics for the chronic treatment of optic neuritis in neuromyelitis optica spectrum disorders in Japan.Japanese journal of ophthalmology · 2025Article
- Imaging Transcriptomics of Brain Functional Alterations in MS and Neuromyelitis Optica Spectrum Disorder.AJNR. American journal of neuroradiology · 2024Article
- Asymptomatic spinal lesions in patients with AQP4-IgG-positive NMOSD: A real-world cohort study.Annals of clinical and translational neurology · 2024Article
- Perspectives on Neuromyelitis Optica Spectrum Disorders, the Narrative Medicine contribution to care.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean.Neurology(R) neuroimmunology & neuroinflammation · 2024Observational
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe diagnostic criteria of neuromyelitis optica spectrum disorders (NMOSD) has been revised in the past 20 years and pathological and therapeutic data have been accumulated. This review provides an overview of evolution and broadening of the concept of NMOSD. RECENT
findingsNMOSD encompassing brain syndrome as well as optic neuritis and acute myelitis is now classified into aquaporine-4 (AQP)-antibody-seropositive and aquaporine-4 (AQP)-antibody-seronegative diseases, detecting more patients earlier than before. Seronegative NMOSD includes cases of myelin oligodendrocyte glycoprotein (MOG)-antibody-seropositive disease with its unique clinical spectrum somewhat different from AQP4-antibody-seropositive NMOSD. Pathologically, NMOSD includes AQP4-antibody-seropositive autoimmune astrocytopathic disease and MOG-antibody-seropositive inflammatory demyelinating disease. Double seronegative group needs further research. Therapeutic options of NMOSD has taken shape and first-ever clinical trials of monoclonal antibodies have been done. In retrospect, relapsing NMO in the studies preceding the discovery of AQP4-antibody had features of AQP4-antibody-seropositive NMO whereas monophasic NMO was similar to AQP4-antibody-seronegative/MOG-antibody-seropositive NMO. SUMMARY: The clinical, pathological and therapeutic concepts of NMOSD have evolved and broadened over the last two decades following the detection of AQP4 antibodies and MOG antibodies in the patients. Double seronegative NMOSD is a current research focus, but now we may need to reconsider how NMOSD should be defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.